Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xu Chao

Showing results (181-190 of 281) with videos related to

Pageof 29
Sort By:
The International Journal of Biological Markers|March 7, 2015
Single nucleotide polymorphisms in VTI1A gene contribute to the susceptibility of Chinese population to non-small cell lung cancerWen-Mei Su, Zhi-Hong Chen, Xu-Chao Zhang, et al.
Journal of Thoracic Disease|November 12, 2015
Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosisWen-Zhao Zhong, Wei Li, Xue-Ning Yang, et al.
Journal of Translational Medicine|July 12, 2013
Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapiesXu-chao Zhang, Jingchuan Zhang, Ming Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2017
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858RE-E Ke, Qing Zhou, Qiu-Yi Zhang, et al.
Therapeutic Advances in Medical Oncology|February 9, 2024
Plasma ddPCR for the detection of <i>MET</i> amplification in advanced NSCLC patients: a comparative real-world studyJun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, et al.
Clinical and Translational Medicine|June 9, 2020
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphismSi-Yang Liu, Jia-Ying Zhou, Wen-Feng Li, et al.
Molecular Carcinogenesis|April 17, 2023
Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancerXiao-Rong Yang, Can Pi, Yi-Chen Zhang, et al.
Cancer Treatment and Research Communications|January 30, 2023
The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patientsYu-Qing Chen, Ling-Ling Gao, Ling-Cong Kong, et al.
BMC Medicine|June 1, 2022
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastasesMei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, et al.
The Oncologist|September 17, 2014
Lung cancer treatment disparities in China: a question in need of an answerLu-Lu Yang, Xu-Chao Zhang, Xue-Ning Yang, et al.
Pageof 29

Showing results (181-190 of 281) with videos related to

Sort By:
Pageof 29
The International Journal of Biological Markers|March 7, 2015
Single nucleotide polymorphisms in VTI1A gene contribute to the susceptibility of Chinese population to non-small cell lung cancerWen-Mei Su, Zhi-Hong Chen, Xu-Chao Zhang, et al.
Journal of Thoracic Disease|November 12, 2015
Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosisWen-Zhao Zhong, Wei Li, Xue-Ning Yang, et al.
Journal of Translational Medicine|July 12, 2013
Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapiesXu-chao Zhang, Jingchuan Zhang, Ming Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2017
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858RE-E Ke, Qing Zhou, Qiu-Yi Zhang, et al.
Therapeutic Advances in Medical Oncology|February 9, 2024
Plasma ddPCR for the detection of <i>MET</i> amplification in advanced NSCLC patients: a comparative real-world studyJun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, et al.
Clinical and Translational Medicine|June 9, 2020
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphismSi-Yang Liu, Jia-Ying Zhou, Wen-Feng Li, et al.
Molecular Carcinogenesis|April 17, 2023
Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancerXiao-Rong Yang, Can Pi, Yi-Chen Zhang, et al.
Cancer Treatment and Research Communications|January 30, 2023
The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patientsYu-Qing Chen, Ling-Ling Gao, Ling-Cong Kong, et al.
BMC Medicine|June 1, 2022
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastasesMei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, et al.
The Oncologist|September 17, 2014
Lung cancer treatment disparities in China: a question in need of an answerLu-Lu Yang, Xu-Chao Zhang, Xue-Ning Yang, et al.
Pageof 29